Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review
As immunotherapies including tyrosine kinase inhibitors become more widely used for the treatment of a variety of malignancies, it is important for prescribers and patients to understand the potential adverse effects associated with these drugs. It is especially important to understand the potential...
Gespeichert in:
| Veröffentlicht in: | Oncotarget 2018-06, Vol.9 (46), p.28281-28289 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 28289 |
|---|---|
| container_issue | 46 |
| container_start_page | 28281 |
| container_title | Oncotarget |
| container_volume | 9 |
| creator | Chae, Young Kwang Chiec, Lauren Adney, Scott K Waitzman, Josh Costa, Ricardo Carneiro, Benedito Matsangou, Maria Agulnik, Mark Kopp, Peter Giles, Frank |
| description | As immunotherapies including tyrosine kinase inhibitors become more widely used for the treatment of a variety of malignancies, it is important for prescribers and patients to understand the potential adverse effects associated with these drugs. It is especially important to understand the potentially fatal side effects associated with these drugs to further determine risk factors for their development. The review presents a case of posterior reversible encephalopathy syndrome with concomitant Takotsubo cardiomyopathy, associated with use of lenvatinib therapy for thyroid cancer. It discusses the interventions performed and outcome. Potential mechanisms for development of these rare adverse effects, as well as cases in which these adverse effects are seen with use of other tyrosine-kinase inhibitors will be presented. It is important to continue to report these side effects, and further studies are needed to elucidate potential risk factors for their development, as well as to determine prognosis after development. |
| doi_str_mv | 10.18632/oncotarget.25606 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6021337</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2063720104</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3146-a5f4ac2475969fb0e1e27fbe272c929cae660466f363a79f6bd168c0c46dc193</originalsourceid><addsrcrecordid>eNpVkc1O3DAUha2KqiDKA3SDvGQz4J_EGbOohBAtlZDaBXvrxrkhLomd2p5BeZS-ba1hoOCFfSWfc74rHUK-cHbO10qKi-BtyBAfMJ-LWjH1gRxxXemVqGt58GY-JCcp_Wbl1FWzFvoTORRal4SmOSJ_f4WUMboQacQtxuTaESl6i_MAY5ghDwtNi-9imJCC72iGx5DTpg3UQuxcmJa9ClIK1kHGjj65PNAR_Ray866lecAI80L7ginSGFxX3AUSLymUKWGhzyHmHaEs4vDpM_nYw5jwZP8ek_tvN_fXt6u7n99_XF_drazklVpB3VdgRdXUWum-ZchRNH1bLmG10BZQKVYp1UslodG9ajuu1pbZSnWWa3lMvj7Hzpt2ws6izxFGM0c3QVxMAGfe_3g3mIewNYoJLmVTAs72ATH82WDKZnLJ4jiCx7BJRjAlG8E4q4qUP0ttDClF7F8xnJldqeZ_qWZXavGcvt3v1fFSofwHNEmmnA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2063720104</pqid></control><display><type>article</type><title>Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review</title><source>PubMed Central Open Access</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Free E- Journals</source><creator>Chae, Young Kwang ; Chiec, Lauren ; Adney, Scott K ; Waitzman, Josh ; Costa, Ricardo ; Carneiro, Benedito ; Matsangou, Maria ; Agulnik, Mark ; Kopp, Peter ; Giles, Frank</creator><creatorcontrib>Chae, Young Kwang ; Chiec, Lauren ; Adney, Scott K ; Waitzman, Josh ; Costa, Ricardo ; Carneiro, Benedito ; Matsangou, Maria ; Agulnik, Mark ; Kopp, Peter ; Giles, Frank</creatorcontrib><description>As immunotherapies including tyrosine kinase inhibitors become more widely used for the treatment of a variety of malignancies, it is important for prescribers and patients to understand the potential adverse effects associated with these drugs. It is especially important to understand the potentially fatal side effects associated with these drugs to further determine risk factors for their development. The review presents a case of posterior reversible encephalopathy syndrome with concomitant Takotsubo cardiomyopathy, associated with use of lenvatinib therapy for thyroid cancer. It discusses the interventions performed and outcome. Potential mechanisms for development of these rare adverse effects, as well as cases in which these adverse effects are seen with use of other tyrosine-kinase inhibitors will be presented. It is important to continue to report these side effects, and further studies are needed to elucidate potential risk factors for their development, as well as to determine prognosis after development.</description><identifier>ISSN: 1949-2553</identifier><identifier>EISSN: 1949-2553</identifier><identifier>DOI: 10.18632/oncotarget.25606</identifier><identifier>PMID: 29963277</identifier><language>eng</language><publisher>United States: Impact Journals LLC</publisher><subject>Review</subject><ispartof>Oncotarget, 2018-06, Vol.9 (46), p.28281-28289</ispartof><rights>Copyright: © 2018 Chae et al. 2018</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3146-a5f4ac2475969fb0e1e27fbe272c929cae660466f363a79f6bd168c0c46dc193</citedby><cites>FETCH-LOGICAL-c3146-a5f4ac2475969fb0e1e27fbe272c929cae660466f363a79f6bd168c0c46dc193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021337/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6021337/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29963277$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chae, Young Kwang</creatorcontrib><creatorcontrib>Chiec, Lauren</creatorcontrib><creatorcontrib>Adney, Scott K</creatorcontrib><creatorcontrib>Waitzman, Josh</creatorcontrib><creatorcontrib>Costa, Ricardo</creatorcontrib><creatorcontrib>Carneiro, Benedito</creatorcontrib><creatorcontrib>Matsangou, Maria</creatorcontrib><creatorcontrib>Agulnik, Mark</creatorcontrib><creatorcontrib>Kopp, Peter</creatorcontrib><creatorcontrib>Giles, Frank</creatorcontrib><title>Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review</title><title>Oncotarget</title><addtitle>Oncotarget</addtitle><description>As immunotherapies including tyrosine kinase inhibitors become more widely used for the treatment of a variety of malignancies, it is important for prescribers and patients to understand the potential adverse effects associated with these drugs. It is especially important to understand the potentially fatal side effects associated with these drugs to further determine risk factors for their development. The review presents a case of posterior reversible encephalopathy syndrome with concomitant Takotsubo cardiomyopathy, associated with use of lenvatinib therapy for thyroid cancer. It discusses the interventions performed and outcome. Potential mechanisms for development of these rare adverse effects, as well as cases in which these adverse effects are seen with use of other tyrosine-kinase inhibitors will be presented. It is important to continue to report these side effects, and further studies are needed to elucidate potential risk factors for their development, as well as to determine prognosis after development.</description><subject>Review</subject><issn>1949-2553</issn><issn>1949-2553</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><recordid>eNpVkc1O3DAUha2KqiDKA3SDvGQz4J_EGbOohBAtlZDaBXvrxrkhLomd2p5BeZS-ba1hoOCFfSWfc74rHUK-cHbO10qKi-BtyBAfMJ-LWjH1gRxxXemVqGt58GY-JCcp_Wbl1FWzFvoTORRal4SmOSJ_f4WUMboQacQtxuTaESl6i_MAY5ghDwtNi-9imJCC72iGx5DTpg3UQuxcmJa9ClIK1kHGjj65PNAR_Ray866lecAI80L7ginSGFxX3AUSLymUKWGhzyHmHaEs4vDpM_nYw5jwZP8ek_tvN_fXt6u7n99_XF_drazklVpB3VdgRdXUWum-ZchRNH1bLmG10BZQKVYp1UslodG9ajuu1pbZSnWWa3lMvj7Hzpt2ws6izxFGM0c3QVxMAGfe_3g3mIewNYoJLmVTAs72ATH82WDKZnLJ4jiCx7BJRjAlG8E4q4qUP0ttDClF7F8xnJldqeZ_qWZXavGcvt3v1fFSofwHNEmmnA</recordid><startdate>20180615</startdate><enddate>20180615</enddate><creator>Chae, Young Kwang</creator><creator>Chiec, Lauren</creator><creator>Adney, Scott K</creator><creator>Waitzman, Josh</creator><creator>Costa, Ricardo</creator><creator>Carneiro, Benedito</creator><creator>Matsangou, Maria</creator><creator>Agulnik, Mark</creator><creator>Kopp, Peter</creator><creator>Giles, Frank</creator><general>Impact Journals LLC</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20180615</creationdate><title>Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review</title><author>Chae, Young Kwang ; Chiec, Lauren ; Adney, Scott K ; Waitzman, Josh ; Costa, Ricardo ; Carneiro, Benedito ; Matsangou, Maria ; Agulnik, Mark ; Kopp, Peter ; Giles, Frank</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3146-a5f4ac2475969fb0e1e27fbe272c929cae660466f363a79f6bd168c0c46dc193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Review</topic><toplevel>online_resources</toplevel><creatorcontrib>Chae, Young Kwang</creatorcontrib><creatorcontrib>Chiec, Lauren</creatorcontrib><creatorcontrib>Adney, Scott K</creatorcontrib><creatorcontrib>Waitzman, Josh</creatorcontrib><creatorcontrib>Costa, Ricardo</creatorcontrib><creatorcontrib>Carneiro, Benedito</creatorcontrib><creatorcontrib>Matsangou, Maria</creatorcontrib><creatorcontrib>Agulnik, Mark</creatorcontrib><creatorcontrib>Kopp, Peter</creatorcontrib><creatorcontrib>Giles, Frank</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Oncotarget</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chae, Young Kwang</au><au>Chiec, Lauren</au><au>Adney, Scott K</au><au>Waitzman, Josh</au><au>Costa, Ricardo</au><au>Carneiro, Benedito</au><au>Matsangou, Maria</au><au>Agulnik, Mark</au><au>Kopp, Peter</au><au>Giles, Frank</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review</atitle><jtitle>Oncotarget</jtitle><addtitle>Oncotarget</addtitle><date>2018-06-15</date><risdate>2018</risdate><volume>9</volume><issue>46</issue><spage>28281</spage><epage>28289</epage><pages>28281-28289</pages><issn>1949-2553</issn><eissn>1949-2553</eissn><abstract>As immunotherapies including tyrosine kinase inhibitors become more widely used for the treatment of a variety of malignancies, it is important for prescribers and patients to understand the potential adverse effects associated with these drugs. It is especially important to understand the potentially fatal side effects associated with these drugs to further determine risk factors for their development. The review presents a case of posterior reversible encephalopathy syndrome with concomitant Takotsubo cardiomyopathy, associated with use of lenvatinib therapy for thyroid cancer. It discusses the interventions performed and outcome. Potential mechanisms for development of these rare adverse effects, as well as cases in which these adverse effects are seen with use of other tyrosine-kinase inhibitors will be presented. It is important to continue to report these side effects, and further studies are needed to elucidate potential risk factors for their development, as well as to determine prognosis after development.</abstract><cop>United States</cop><pub>Impact Journals LLC</pub><pmid>29963277</pmid><doi>10.18632/oncotarget.25606</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1949-2553 |
| ispartof | Oncotarget, 2018-06, Vol.9 (46), p.28281-28289 |
| issn | 1949-2553 1949-2553 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6021337 |
| source | PubMed Central Open Access; EZB-FREE-00999 freely available EZB journals; PubMed Central; Free E- Journals |
| subjects | Review |
| title | Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T14%3A52%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Posterior%20reversible%20encephalopathy%20syndrome%20and%20takotsubo%20cardiomyopathy%20associated%20with%20lenvatinib%20therapy%20for%20thyroid%20cancer:%20a%20case%20report%20and%20review&rft.jtitle=Oncotarget&rft.au=Chae,%20Young%20Kwang&rft.date=2018-06-15&rft.volume=9&rft.issue=46&rft.spage=28281&rft.epage=28289&rft.pages=28281-28289&rft.issn=1949-2553&rft.eissn=1949-2553&rft_id=info:doi/10.18632/oncotarget.25606&rft_dat=%3Cproquest_pubme%3E2063720104%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2063720104&rft_id=info:pmid/29963277&rfr_iscdi=true |